Structure Therapeutics Inc. (GPCR)
 NASDAQ: GPCR · Real-Time Price · USD
 33.32
 +1.10 (3.41%)
  At close: Oct 31, 2025, 4:00 PM EDT
33.51
 +0.19 (0.57%)
  After-hours: Oct 31, 2025, 7:07 PM EDT
Structure Therapeutics Employees
Structure Therapeutics had 163 employees as of December 31, 2024. The number of employees increased by 70 or 75.27% compared to the previous year.
Employees 
 163
Change (1Y) 
 70
Growth (1Y) 
 75.27%
Revenue / Employee 
 n/a
Profits / Employee 
 -$1,097,853
Market Cap 
1.92B
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 163 | 70 | 75.27% | 
| Dec 31, 2023 | 93 | 25 | 36.76% | 
| Dec 31, 2022 | 68 | - | - | 
Related Stocks
| Company Name | Employees | 
|---|---|
| UnitedHealth Group | 400,000 | 
| Johnson & Johnson | 138,100 | 
| Thermo Fisher Scientific | 125,000 | 
| Abbott Laboratories | 114,000 | 
| AstraZeneca | 92,900 | 
| Novo Nordisk | 77,349 | 
| Novartis AG | 75,883 | 
| Merck & Co. | 75,000 | 
GPCR News
- 7 weeks ago - Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 3 months ago - Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights - GlobeNewsWire
- 4 months ago - Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671 - GlobeNewsWire
- 7 months ago - What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? - Benzinga
- 7 months ago - Biotech stocks have been hit hard. Why they're a great value now. - Market Watch
- 8 months ago - Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate - Seeking Alpha
- 9 months ago - Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 10 months ago - Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst - Benzinga